medigraphic.com

2017, Number 4

<< Back Next >>

Rev Med Inst Mex Seguro Soc 2017; 55 (4)

ANCA-associated vasculitides at Mexico City’s metropolitan eastern area

Cervera-Castillo H, Blanco-Favela F, Silva-López YF, Paredez-Rivera GE, Torres-Caballero V

Language: Spanish
References: 37
Page: 430-440
PDF size: 357.08 Kb.


ABSTRACT

Background: The anti-neutrophil cytoplasmic antibody-associated (ANCA) vasculitides includes granulomatosis with polyangiitis (Wegener’s) (GPW), Chrug-Strauss syndrome (CSS) and microscopic polyangiitis (MPA). Since it has low incidence in our field, there are a few published papers. The aim of this study was to report the clinical characteristics, activity and damage of these vasculitides in Mexico City’s metropolitan eastern area.
Methods: We studied 28 cases with ANCA-associated vasculitis in the aforementioned area. The classification was made according to the ACR 1990 criteria, the Chapel Hill 2012 consensus, and the EULAR 2007 recommendations. We collected demographic data, as well as data of clinical manifestations, laboratory, management and outcomes. The activity was established using the Birmingham Vasculitis Activity Score (BVAS) and the damage using the Vasculitis Damage Index (VDI). We used paired t test and 95% confidence intervals (95% CI).
Results: 15 females and 13 males were included, 20 with GPW and 8 with CCS. The mean age was 50.1 ± 12.7 years, and the evolution time was 69 ± 49.6 months. We didn’t find cases of MAP. 23 patients (82.1%) had general symptoms. The initial and fi nal BVAS means were 10.5 and 1.5 (p ‹ 0.001) and the global VDI was 2.4.
Conclusions: The presence of ANCA-associated vasculitides is rare in the eastern Metropolitan area of Mexico City. GPW was predominant over CCS, and MPA was absent. They are multi-system vasculitides with high scores of initial activity and moderate damage.


REFERENCES

  1. Miller A, Chan M, Wiik A, Misbah SA, Luqmani RA. An approach to the diagnosis and management of systemic vasculitis. Clin Exp Immunol. 2010 May;160(2):143- 60. doi: 10.1111/j.1365-2249.2009.04078.x.

  2. Watts R, Lane S, Hanslik T, Hauser T, Hellmich B, Koldingsnes W, et al. Development and validation of a consensus methodology for the classifi cation of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies. Ann Rheum Dis. 2007;66(6):222-7.

  3. Falk RJ, Gross WL, Guillvein L, Hoffman GS, Jayne DRW, Jennette JC, et al. Granulomatosis with polyangiitis (Wegener’s): an alternative name for Wegener’s granulomatosis. Arthritis Rheum. 2011;63(4):863-4. doi: 10.1002/art.30286.

  4. Jannette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrairo F, et al. 2012 revised international Chapell Hill consensus conference nomenclature of vasculitides. Arthritis Rheum. 2013:65;1-11.

  5. Falk RJ, Nachman PH, Hogan SL, Jennette JC. ANCA glomerulonephritis and vasculitis: a Chapel Hill perspective. Seminars in Nephrology. 2000;20 (3):233-43.

  6. Gibelin A, Maldine C, Mahr A. Epidemiology and etiology of Wegener granulomatosis, microscopic polyangiitis, Churg-Strauss syndrome and Googpasture syndrome: vasculitides with frequent lung involvement Semin Respir Crit Care Med. 2011 Jun;32(3):264-73. doi: 10.1055/s-0031-1279824.

  7. Knight A, Ekbom A, Brandt L, Askling J. Increasing incidence of Wegener’s granulomatosis in Sweden, 1975-2001. J Rheumatol. 2006;33(10):2060-3.

  8. Watts RA, Al-Taiar A, Scott DG, Macgregor AJ. Prevalence and incidence of Wegener’s granulomatosis in the UK general practice research database. Arthritis Rheum. 2009;61(10):1412-6. doi: 10.1002/art.24544.

  9. Ozaki S. ANCA-associated vasculitis: diagnostic and therapeutic strategy. Allergology Int. 2007;56 (2):87-96.

  10. Holle JU, Gross WL, Latza U, Nölle B, Ambrosch P, Heller M, et al. Improved outcome in 445 patients with Wegener’s granulomatosis in a German vasculitis center over four decades. Arthritis Rheum. 2011; 63(1):257-66. doi: 10.1002/art.27763.

  11. Pagnoux C. Churg-Strauss Syndrome: evolving concepts. Discovery Med. 2010; 9(46):243-52.

  12. Lanham JG, Elkon KB, Pusey CD, Hughes GR. Systemic vasculitis with asma and eosinophilia: a clinical approach to the Churg-Strauss syndrome. Medicine (Baltimore). 1984 Mar;63(2):65-81.

  13. Hamour S, Salama AD, Pusey CD. Management of ANCA-associated vasculitis: current trends and future prospects. Ther Clin Risk Manag. 2010 Jun 24; 6:253-64.

  14. Mukhtyar C, Flossmann O, Hellmich B, Bacon P, Cohen- Tervaert JW, Gross WL, et al. Outcomes from studies of antineutrophil cytoplasm antibody associated vasculitis: a systematic review by the European League Against Rheumatism systemic vasculitis task force. Ann Rheum Dis. 2008;67(6):1004-10.

  15. Leavitt RY, Fauci AS, Bloch DA, Michel BA, Hunder GG, Arend WP, et al. The American College of Rheumatology 1990 criteria for the classifi cation of Wegener’s granulomatosis. Arthritis Rheum. 1990; 33(8):1101-7.

  16. Masi AT, Hunder GG, Lie JT, Michel BA, Bloch DA, Arend WP, et al. The American College of Rheumatology 1990 criteria for the classifi cation of Churg Strauss syndrome (allergic granulomatosis and angiitis). Arthritis Rheum. 1990;33(8):1094-100.

  17. Mukhtyar C, Lee R, Brown D, Carruthers D, Dasgupta B, Dubey, et al. Modifi cation and validation of the Birmingham vasculitis activity score (version 3). Ann Rheum Dis. 2009 Dec;68(12):1827-32. doi: 10.1136/ ard.2008.101279.

  18. Exley AR, Bacon PA, Luqmani RA, Kitas GD, Gordon C, Savage CO, et al. Development and initial validation of the Vasculitis Damage Index for the standardized clinical assessment of damage in the systemic vasculitides. Arthritis Rheum. 1997;40(2):371-80.

  19. Paolini MV, Ruffi no JP, Fernández-Romero DS. Vasculitis asociadas a anticuerpos anti-citoplasma de neutrofi los. Clínica y tratamiento. Medicina (B. Aires). 2013;73(2):119-26.

  20. Flores-Padilla G, Ávila-Beltrán RR, Moncada-Tobías E. Poliangeítis microscópica y glomerulonefritis de progresión rápida: importancia del diagnóstico y tratamiento oportuno. Reporte de un caso. Med Int Mex. 2006;22:253-6.

  21. Zazueta-Montiel B, Flores Suárez LF. Ruta y retos diagnósticos en vasculitis primarias. Reumatol Clin. 2011 Dec;7 Suppl 3:S1-6. doi: 10.1016/j.reuma.2011.10.001.

  22. Ochoa CD, Ramírez F, Quintana G, Toro C, Cañas C, Osio LF, et al. Epidemiología de las vasculitis primarias en Colombia y su relación con lo informado para Latinoamérica. Rev Col de Reumatol. 2009;16 (3):248- 63. http://dx.doi.org/10.1016/S0121-8123(09)70103-3

  23. Sánchez-Torres A, Acevedo-Vásquez E, Sánchez- Schwartz C, Pastor-Asurza C, Perich-Campos R, Alfaro-Lozano J, et al. Epidemiología de las vasculitis sistémicas primarias en una población latinoamericana. Reumatología. 2005;21(3):145-50.

  24. Cisternas MM, Soto SL, Jacobelli GS, Marinovic MA, Vargas BA, Sobarzo VE et al. Manifestaciones clínicas de la granulomatosis de Wegener y la poliangeítis microscópica en Santiago-Chile, 1990- 2001. Rev Med Chile. 2005;133(3):273-8.

  25. Abdou NI, Kullman GJ, Hoffman GS, Sharp GC, Specks U, McDonald T, et al. Wegener´s granulomatosis: survey of 701 patients in North America. Changes in outcome in the 1990s. J Rheumatol. 2002;29(2):309-16.

  26. Solans R, Bosch JA, Pérez-Bocanegra C, Selva A, Huguet P, Alijotas J, et al. Churg-Strauss syndrome: outcome and long-term follow-up of 32 patients. Rheumatology. 2001;40(1):763-71.

  27. Stone JH, Hoffman GS, Merkel PA, Min YI, Uhlfelder ML, Hellmann DB, et al. A disease-specifi c activity index for Wegener’s granulomatosis: modifi cation of the Birmingham Vasculitis Activity Score. International Network for the Study of the Systemic Vasculitides (INSSYS). Arthritis Rheum. 2001;44(4):912-20.

  28. Davenport A. “False positive” perinuclear and cytoplasmatic anti-neutrophil cytoplasmic antibody results leading to misdiagnosis of Wegener’s granulomatosis and/or microscopic polyarteritis. Clin Nephron. 1992;37(3):124-30.

  29. Specks U, Wheatley CL, McDonald TJ, Rohrbach MS, DeRemee RA. Anticytoplasmic autoantibodies in the diagnosis and follow-up of Wegener’s granulomatosis. Mayo Clin Proc. 1989;64(1):28-36.

  30. Guillevin L, Cordier JF, Lhote F, Cohen P, Jarrousse B, Royer I, et al. A prospective, multicenter, randomized trial comparing steroids and pulse cyclophosphamide versus steroids and oral cyclophosphamide in the treatment of generalized Wegener’s granulomatosis. Arthritis Rheum. 1997;40(12):2187-98.

  31. Dadoniene J, Pileckyte M, Baranauskaite A, Kirdaite G. Clinical characteristics and long-term outcomes of 35 patients with Wegener’s granulomatosis followed up at two rheumatology centers in Lithuania. Medicina (Kaunas) 2010(4);46:256-60.

  32. DeRemee RA. The treatment of Wegener’s granulomatosis with trimethroprim/sulfamethoxazole: illusion or vision? Arthritis Rheum 1988;31(8):1068-74.

  33. Cervera-Castillo H, Torres-Caballero V, Martínez- García E, Pizaña.Serna M, Blanco-Favela FA. Granulomatosis de Wegener: estado de portador de Staphylococcus aureus y terapéutica combinada. Rev Med Inst Mex Seguro Soc. 2006;44(3):249-55.

  34. Langford CA, Talar-Williams C, Barron KS, Sneller MC. A Staged approach to the treatment of Wegener’s granulomatosis: induction of remission with glucocorticoids and daily cyclophosphamide switching to methotrexate for remission maintenance. Arthritis Rheum. 1999;42(12):2666-73.

  35. Stone JH, Merkel PA, Spiera R, Seo P, Langford CA, Hoffman GS. Rituximab versus cyclophosphamide for ANCA associated vasculitis. N Engl J Med. 2010; 363(3):221-32.

  36. Jones RB, Furuta S, Cohen Tervaert JW, Hauser T, Luqmani R, Morgan MD, et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis: 2-year results of a randomized trial. Ann Rheum Dis. 2015;74(6):1178-82. doi: 10.1136/ annrheumdis-2014-206404.

  37. Mahr AD, Neogi T, Merkel PA. Epidemiology of Wegener’s granulomatosis: lessons from descriptive studies and analyses of genetic and environmental risk determinants. Clin Exp Rheumatol. 2006 Mar-Apr;24(2 Suppl 41):S82-91.




2020     |     www.medigraphic.com